Interleukin 6 Explained

Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. In humans, it is encoded by the IL6 gene.[1]

In addition, osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine. IL-6's role as an anti-inflammatory myokine is mediated through its inhibitory effects on TNF-alpha and IL-1 and its activation of IL-1ra and IL-10.

There is some early evidence that IL-6 can be used as an inflammatory marker for severe COVID-19 infection with poor prognosis, in the context of the wider coronavirus pandemic.[2]

Function

Immune system

IL-6 is secreted by macrophages in response to specific microbial molecules, referred to as pathogen-associated molecular patterns (PAMPs). These PAMPs bind to an important group of detection molecules of the innate immune system, called pattern recognition receptors (PRRs), including Toll-like receptors (TLRs). These are present on the cell surface and intracellular compartments and induce intracellular signaling cascades that give rise to inflammatory cytokine production. IL-6 is an important mediator of fever and of the acute phase response.

IL-6 is responsible for stimulating acute phase protein synthesis, as well as the production of neutrophils in the bone marrow. It supports the growth of B cells and is antagonistic to regulatory T cells.

Metabolic

It is capable of crossing the blood–brain barrier[3] and initiating synthesis of PGE2 in the hypothalamus, thereby changing the body's temperature setpoint. In muscle and fatty tissue, IL-6 stimulates energy mobilization that leads to increased body temperature. At 4°C, both the oxygen consumption and core temperature were lower in IL-6-/- compared with wild-type mice, suggesting a lower cold-induced thermogenesis in IL-6-/- mice.[4]

In the absence of inflammation 10–35% of circulating IL-6 may come from adipose tissue. IL-6 is produced by adipocytes and is thought to be a reason why obese individuals have higher endogenous levels of CRP.[5] IL-6 may exert a tonic suppression of body fat in mature mice, given that IL-6 gene knockout causes mature onset obesity.[6] [7] [8] Moreover, IL-6 can suppress body fat mass via effects at the level of the CNS. The antiobesity effect of IL-6 in rodents is exerted at the level of the brain, presumably the hypothalamus and the hindbrain.[9] [10] [11] On the other hand, enhanced central IL-6 trans-signaling may improve energy and glucose homeostasis in obesity[12] Trans-signaling implicates that a soluble form of IL-6R (sIL-6R) comprising the extracellular portion of the receptor can bind IL-6 with a similar affinity as the membrane bound IL-6R. The complex of IL-6 and sIL-6R can bind to gp130 on cells, which do not express the IL-6R, and which are unresponsive to IL-6.

Studies in experimental animals indicate that IL-6 in the CNS partly mediates the suppression of food intake and body weight exerted by glucagon-like peptide-1 (GLP-1) receptor stimulation.[13]

Outside the CNS, it seems that IL-6 stimulates the production of GLP-1 in the endocrine pancreas and the gut.[14] Amylin is another substance that can reduce body weight, and that may interact with IL-6. Amylin-induced IL-6 production in the ventromedial hypothalamus (VMH) is a possible mechanism by which amylin treatment could interact with VMH leptin signaling to increase its effect on weight loss.[15]

It is assumed that interleukin 6 in the liver activates the homologue of the human longevity gene mINDY expression via binding to its IL-6-receptor, which is associated with activation of the transcription factor STAT3 (which binds to the binding site in the mIndy promoter) and thereby rise of citrate uptake and hepatic lipogenesis.[16] [17]

Central nervous system

Intranasally administered IL-6 has been shown to improve sleep-associated consolidation of emotional memories.[18]

There are indications of interactions between GLP-1 and IL-6 in several parts of the brain. One example is the parabrachial nuclei of the pons, where GLP-1 increases IL-6 levels[19] [20] and where IL-6 exerts a marked anti-obesity effect.[21]

Role as myokine

IL-6 is also considered a myokine, a cytokine produced from muscle, which is elevated in response to muscle contraction.[22] It is significantly elevated with exercise, and precedes the appearance of other cytokines in the circulation. During exercise, it is thought to act in a hormone-like manner to mobilize extracellular substrates and/or augment substrate delivery.[23]

Like in humans, there seems to be an increase in IL-6 expression in working muscle and plasma IL-6 concentration during exercise in rodents.[24] [25] Studies in mice with IL-6 gene knockout indicate that lack of IL-6 in mice affect exercise function.[26]

It has been shown that the reduction of abdominal obesity by exercise in human adults can be reversed by the IL-6 receptor blocking antibody tocilizumab. Together with the findings that IL-6 prevents obesity, stimulates lipolysis and is released from skeletal muscle during exercise, the tocilizumab finding indicates that IL-6 is required for exercise to reduce visceral adipose tissue mass.[27] Bone may be another organ affected by exercise induced IL-6, given that muscle-derived interleukin 6 has been reported to increase exercise capacity by signaling in osteoblasts.[28]

IL-6 has extensive anti-inflammatory functions in its role as a myokine. IL-6 was the first myokine that was found to be secreted into the blood stream in response to muscle contractions.[29] Aerobic exercise provokes a systemic cytokine response, including, for example, IL-6, IL-1 receptor antagonist (IL-1ra), and IL-10. IL-6 was serendipitously discovered as a myokine because of the observation that it increased in an exponential fashion proportional to the length of exercise and the amount of muscle mass engaged in the exercise. It has been consistently demonstrated that the plasma concentration of IL-6 increases during muscular exercise. This increase is followed by the appearance of IL-1ra and the anti-inflammatory cytokine IL-10. In general, the cytokine response to exercise and sepsis differs with regard to TNF-α. Thus, the cytokine response to exercise is not preceded by an increase in plasma-TNF-α. Following exercise, the basal plasma IL-6 concentration may increase up to 100-fold, but less dramatic increases are more frequent. The exercise-induced increase of plasma IL-6 occurs in an exponential manner and the peak IL-6 level is reached at the end of the exercise or shortly thereafter. It is the combination of mode, intensity, and duration of the exercise that determines the magnitude of the exercise-induced increase of plasma IL-6.[30]

IL-6 had previously been classified as a proinflammatory cytokine. Therefore, it was first thought that the exercise-induced IL-6 response was related to muscle damage.[31] However, it has become evident that eccentric exercise is not associated with a larger increase in plasma IL-6 than exercise involving concentric "nondamaging" muscle contractions. This finding clearly demonstrates that muscle damage is not required to provoke an increase in plasma IL-6 during exercise. As a matter of fact, eccentric exercise may result in a delayed peak and a much slower decrease of plasma IL-6 during recovery.

Recent work has shown that both upstream and downstream signalling pathways for IL-6 differ markedly between myocytes and macrophages. It appears that unlike IL-6 signalling in macrophages, which is dependent upon activation of the NFκB signalling pathway, intramuscular IL-6 expression is regulated by a network of signalling cascades, including the /NFAT and glycogen/p38 MAPK pathways. Thus, when IL-6 is signalling in monocytes or macrophages, it creates a pro-inflammatory response, whereas IL-6 activation and signalling in muscle is totallyindependent of a preceding TNF-response or NFκB activation, and is anti-inflammatory.[32]

IL-6, among an increasing number of other recently identified myokines, thus remains an important topic in myokine research. It appears in muscle tissue and in the circulation during exercise at levels up to one hundred times basal rates, as noted, and is seen as having a beneficial impact on health and bodily functioning when elevated in response to physical exercise.[33]

Receptor

See main article: Interleukin-6 receptor. IL-6 signals through a cell-surface type I cytokine receptor complex consisting of the ligand-binding IL-6Rα chain (CD126), and the signal-transducing component gp130 (also called CD130). CD130 is the common signal transducer for several cytokines including leukemia inhibitory factor (LIF), ciliary neurotropic factor, oncostatin M, IL-11 and cardiotrophin-1, and is almost ubiquitously expressed in most tissues. In contrast, the expression of CD126 is restricted to certain tissues. As IL-6 interacts with its receptor, it triggers the gp130 and IL-6R proteins to form a complex, thus activating the receptor. These complexes bring together the intracellular regions of gp130 to initiate a signal transduction cascade through certain transcription factors, Janus kinases (JAKs) and Signal Transducers and Activators of Transcription (STATs).[34]

IL-6 is probably the best-studied of the cytokines that use gp130, also known as IL-6 signal transducer (IL6ST), in their signalling complexes. Other cytokines that signal through receptors containing gp130 are Interleukin 11 (IL-11), Interleukin 27 (IL-27), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), leukemia inhibitory factor (LIF), oncostatin M (OSM), Kaposi's sarcoma-associated herpesvirus interleukin 6-like protein (KSHV-IL6).[35] These cytokines are commonly referred to as the IL-6 like or gp130 utilising cytokines [36]

In addition to the membrane-bound receptor, a soluble form of IL-6R (sIL-6R) has been purified from human serum and urine. Many neuronal cells are unresponsive to stimulation by IL-6 alone, but differentiation and survival of neuronal cells can be mediated through the action of sIL-6R. The sIL-6R/IL-6 complex can stimulate neurites outgrowth and promote survival of neurons and, hence, may be important in nerve regeneration through remyelination.

Interactions

Interleukin-6 has been shown to interact with interleukin-6 receptor,[37] [38] [39] glycoprotein 130,[40] and Galectin-3.[41]

There is considerable functional overlap and interaction between Substance P (SP), the natural ligand for the neurokinin type 1 receptor (NK1R, a mediator of immunomodulatory activity) and IL-6.

Role in disease

IL-6 stimulates the inflammatory and auto-immune processes in many diseases such as multiple sclerosis,[42] neuromyelitis optica spectrum disorder (NMOSD), diabetes,[43] atherosclerosis,[44] gastric cancer,[45] depression,[46] Alzheimer's disease,[47] systemic lupus erythematosus,[48] multiple myeloma,[49] prostate cancer,[50] Behçet's disease,[51] rheumatoid arthritis,[52] and intracerebral hemorrhage.[53]

Hence, there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.[54] [55] The first such is tocilizumab, which has been approved for rheumatoid arthritis,[56] Castleman's disease[57] and systemic juvenile idiopathic arthritis.[58] Others are in clinical trials.[59] It has been observed that genetic inactivation of ZCCHC 6 suppresses IL‐6 expression and reduces the severity of experimental osteoarthritis in Mice.[60] Some plant derived small molecule such as Butein have been reported to inhibit IL-6 expression in IL-1β stimulated human chondrocytes.[61]

Liver diseases

Since IL-6 is a well-known pleiotropic molecule, it plays a dual role in the pathogenesis of liver diseases. While it is necessary for promoting liver regeneration,[62] IL-6 is also a highly recognized marker of systemic inflammation and its association with mortality in liver diseases has been reported by multiple studies.[63] [64] [65] [66] [67] In patients with severe alcohol-associated hepatitis, IL-6 showed the most robust elevation among inflammatory cytokines compared to healthy controls with a further increase in non-survivors. In these patients, IL-6 was a predictor of short-term (28- and 90-day) mortality.

Rheumatoid arthritis

The first FDA approved anti-IL-6 treatment was for rheumatoid arthritis.

Cancer

Anti-IL-6 therapy was initially developed for treatment of autoimmune diseases, but due to the role of IL-6 in chronic inflammation, IL-6 blockade was also evaluated for cancer treatment.[68] [69] [70] IL-6 was seen to have roles in tumor microenvironment regulation,[71] [70] production of breast cancer stem cell-like cells,[72] metastasis through down-regulation of E-cadherin,[73] and alteration of DNA methylation in oral cancer.[74]

Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.[75] One example of this is pancreatic cancer, with noted elevation of IL-6 present in patients correlating with poor survival rates.[76]

Diseases

Enterovirus 71

High IL-6 levels are associated with the development of encephalitis in children and immunodeficient mouse models infected with Enterovirus 71; this highly contagious virus normally causes a milder illness called Hand, foot, and mouth disease but can cause life-threatening encephalitis in some cases. EV71 patients with a certain gene polymorphism in IL-6 also appear to be more susceptible to developing encephalitis.

Epigenetic modifications

IL-6 has been shown to lead to several neurological diseases through its impact on epigenetic modification within the brain.[77] [78] IL-6 activates the Phosphoinositide 3-kinase (PI3K) pathway, and a downstream target of this pathway is the protein kinase B (PKB) (Hodge et al., 2007). IL-6 activated PKB can phosphorylate the nuclear localization signal on DNA methyltransferase-1 (DNMT1).[79] This phosphorylation causes movement of DNMT1 to the nucleus, where it can be transcribed.[79] DNMT1 recruits other DNMTs, including DNMT3A and DNMT3B, which, as a complex, recruit HDAC1.[78] This complex adds methyl groups to CpG islands on gene promoters, repressing the chromatin structure surrounding the DNA sequence and inhibiting transcriptional machinery from accessing the gene to induce transcription.[78] Increased IL-6, therefore, can hypermethylate DNA sequences and subsequently decrease gene expression through its effects on DNMT1 expression.[80]

Schizophrenia

The induction of epigenetic modification by IL-6 has been proposed as a mechanism in the pathology of schizophrenia through the hypermethylation and repression of the GAD67 promoter.[78] This hypermethylation may potentially lead to the decreased GAD67 levels seen in the brains of people with schizophrenia.[81] GAD67 may be involved in the pathology of schizophrenia through its effect on GABA levels and on neural oscillations.[82] Neural oscillations occur when inhibitory GABAergic neurons fire synchronously and cause inhibition of a multitude of target excitatory neurons at the same time, leading to a cycle of inhibition and disinhibition.[82] These neural oscillations are impaired in schizophrenia, and these alterations may be responsible for both positive and negative symptoms of schizophrenia.[83]

Aging

IL-6 is commonly found in the senescence-associated secretory phenotype (SASP) factors secreted by senescent cells (a toxic cell-type that increases with aging).[84] [85] Cancer (a disease that increases with age) invasiveness is promoted primarily though the actions of the SASP factors metalloproteinase, chemokine, IL-6, and interleukin 8 (IL-8).[86] IL-6 and IL-8 are the most conserved and robust features of SASP.[87]

Myelodysplastic Syndromes

IL-6 receptor was found upregulated in high-risk MDS patients. The inhibition of IL-6 signaling pathway can significantly ameliorate the clonogenicity of MDS hematopoietic stem and progenitor cells (HSPCs), but have undetectable effect on normal HSPCs.[70]

Depression and major depressive disorder

The epigenetic effects IL-6 have also been implicated in the pathology of depression. The effects of IL-6 on depression are mediated through the repression of brain-derived neurotrophic factor (BDNF) expression in the brain; DNMT1 hypermethylates the BDNF promoter and reduces BDNF levels.[88] Altered BDNF function has been implicated in depression,[89] which is likely due to epigenetic modification following IL-6 upregulation.[88] BDNF is a neurotrophic factor implicated in spine formation, density, and morphology on neurons.[90] Downregulation of BDNF, therefore, may cause decreased connectivity in the brain. Depression is marked by altered connectivity, in particular between the anterior cingulate cortex and several other limbic areas, such as the hippocampus.[91] The anterior cingulate cortex is responsible for detecting incongruences between expectation and perceived experience.[92] Altered connectivity of the anterior cingulate cortex in depression, therefore, may cause altered emotions following certain experiences, leading to depressive reactions.[92] This altered connectivity is mediated by IL-6 and its effect on epigenetic regulation of BDNF.[88]

Additional preclinical and clinical data, suggest that Substance P [SP] and IL-6 may act in concert to promote major depression. SP, a hybrid neurotransmitter-cytokine, is co-transmitted with BDNF through paleo-spinothalamic circuitry from the periphery with collaterals into key areas of the limbic system. However, both IL6 and SP mitigate expression of BDNF in brain regions associated with negative affect and memory. SP and IL6 both relax tight junctions of the blood brain barrier, such that effects seen in fMRI experiments with these molecules may be a bidirectional mix of neuronal, glial, capillary, synaptic, paracrine, or endocrine-like effects. At the cellular level, SP is noted to increase expression of interleukin-6 (IL-6) through PI-3K, p42/44 and p38 MAP kinase pathways. Data suggest that nuclear translocation of NF-κB regulates IL-6 overexpression in SP-stimulated cells.[93] This is of key interest as: 1) a meta-analysis indicates an association of major depressive disorder, C-reactive protein and IL6 plasma concentrations,[94] 2) NK1R antagonists [five molecules] studied by 3 independent groups in over 2000 patients from 1998 to 2013 validate the mechanism as dose-related, fully effective antidepressant, with a unique safety profile.[95] [96] (see Summary of NK1RAs in Major Depression), 3) the preliminary observation that plasma concentrations of IL6 are elevated in depressed patients with cancer,[97] and 4) selective NK1RAs may eliminate endogenous SP stress-induced augmentation of IL-6 secretion pre-clinically.[98] These and many other reports suggest that a clinical study of a neutralizing IL-6 biological or drug based antagonist is likely warranted in patients with major depressive disorder, with or without co-morbid chronic inflammatory based illnesses; that the combination of NK1RAs and IL6 blockers may represent a new, potentially biomarkable approach to major depression, and possibly bipolar disorder.

The IL-6 antibody sirukumab underwent clinical trials for adjunctive treatment of major depressive disorder in 2015—2018, but this research has been discontinued.[99]

Asthma

Obesity is a known risk factor in the development of severe asthma. Recent data suggests that the inflammation associated with obesity, potentially mediated by IL-6, plays a role in causing poor lung function and increased risk for developing asthma exacerbations.[100]

Protein superfamily

Interleukin is the main member of the IL-6 superfamily, which also includes G-CSF, IL23A, and CLCF1. A viral version of IL6 is found in Kaposi's sarcoma-associated herpesvirus.[101]

See also

External links

Notes and References

  1. Ferguson-Smith AC, Chen YF, Newman MS, May LT, Sehgal PB, Ruddle FH . Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21 . Genomics . 2 . 3 . 203–208 . April 1988 . 3294161 . 10.1016/0888-7543(88)90003-1 .
  2. Web site: Raised troponin and interleukin-6 levels are associated with a poor prognosis in COVID-19 . 2 April 2020 . Cardiac Rhythm News.
  3. Banks WA, Kastin AJ, Gutierrez EG . Penetration of interleukin-6 across the murine blood–brain barrier . Neuroscience Letters . 179 . 1–2 . 53–56 . September 1994 . 7845624 . 10.1016/0304-3940(94)90933-4 . 22712577 .
  4. Wernstedt I, Edgley A, Berndtsson A, Fäldt J, Bergström G, Wallenius V, Jansson JO . Reduced stress- and cold-induced increase in energy expenditure in interleukin-6-deficient mice . American Journal of Physiology. Regulatory, Integrative and Comparative Physiology . 291 . 3 . R551–R557 . September 2006 . 16455769 . 10.1152/ajpregu.00514.2005 .
  5. Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F . Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects . Circulation . 99 . 16 . 2221–2222 . April 1999 . 10217702 . 10.1161/circ.99.16.2219/c . free .
  6. Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO . Interleukin-6-deficient mice develop mature-onset obesity . Nature Medicine . 8 . 1 . 75–79 . January 2002 . 11786910 . 10.1038/nm0102-75 . 7111589 .
  7. Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, Watson N, Zaffino LA, Babb JR, Boon J, Meikle PJ, Jowett JB, Watt MJ, Jansson JO, Bruce CR, Febbraio MA . Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance . Diabetologia . 53 . 11 . 2431–2441 . November 2010 . 20697689 . 10.1007/s00125-010-1865-y . 12970519 .
  8. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA . Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity . American Journal of Physiology. Endocrinology and Metabolism . 287 . 1 . E182–E187 . July 2004 . 15191885 . 10.1152/ajpendo.00189.2003 .
  9. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO . Intracerebroventricular interleukin-6 treatment decreases body fat in rats . Biochemical and Biophysical Research Communications . 293 . 1 . 560–565 . April 2002 . 12054638 . 10.1016/S0006-291X(02)00230-9 .
  10. Sadagurski M, Norquay L, Farhang J, D'Aquino K, Copps K, White MF . Human IL6 enhances leptin action in mice . Diabetologia . 53 . 3 . 525–535 . March 2010 . 19902173 . 2815798 . 10.1007/s00125-009-1580-8 .
  11. Campbell IL, Erta M, Lim SL, Frausto R, May U, Rose-John S, Scheller J, Hidalgo J . Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain . The Journal of Neuroscience . 34 . 7 . 2503–2513 . February 2014 . 24523541 . 6802757 . 10.1523/JNEUROSCI.2830-13.2014 .
  12. Rose-John S . IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6 . International Journal of Biological Sciences . 8 . 9 . 1237–1247 . 2012 . 23136552 . 3491447 . 10.7150/ijbs.4989 .
  13. Shirazi R, Palsdottir V, Collander J, Anesten F, Vogel H, Langlet F, Jaschke A, Schürmann A, Prévot V, Shao R, Jansson JO, Skibicka KP . Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6 . Proceedings of the National Academy of Sciences of the United States of America . 110 . 40 . 16199–16204 . October 2013 . 24048027 . 3791711 . 10.1073/pnas.1306799110 . free . 2013PNAS..11016199S .
  14. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD, Hansen AM, Reinecke M, Konrad D, Gassmann M, Reimann F, Halban PA, Gromada J, Drucker DJ, Gribble FM, Ehses JA, Donath MY . Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells . Nature Medicine . 17 . 11 . 1481–1489 . October 2011 . 22037645 . 4286294 . 10.1038/nm.2513 .
  15. Le Foll C, Johnson MD, Dunn-Meynell AA, Boyle CN, Lutz TA, Levin BE . Amylin-induced central IL-6 production enhances ventromedial hypothalamic leptin signaling . Diabetes . 64 . 5 . 1621–1631 . May 2015 . 25409701 . 4407855 . 10.2337/db14-0645 .
  16. von Loeffelholz C, Lieske S, Neuschäfer-Rube F, Willmes DM, Raschzok N, Sauer IM, König J, Fromm MF, Horn P, Chatzigeorgiou A, Pathe-Neuschäfer-Rube A, Jordan J, Pfeiffer AF, Mingrone G, Bornstein SR, Stroehle P, Harms C, Wunderlich FT, Helfand SL, Bernier M, de Cabo R, Shulman GI, Chavakis T, Püschel GP, Birkenfeld AL . The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism . Hepatology . 66 . 2 . 616–630 . August 2017 . 28133767 . 5519435 . 10.1002/hep.29089 .
  17. Rogina B . INDY-A New Link to Metabolic Regulation in Animals and Humans . Frontiers in Genetics . 8 . 66 . 2017 . 28596784 . 5442177 . 10.3389/fgene.2017.00066 . free .
  18. Benedict C, Scheller J, Rose-John S, Born J, Marshall L . Enhancing influence of intranasal interleukin-6 on slow-wave activity and memory consolidation during sleep . FASEB Journal . 23 . 10 . 3629–3636 . October 2009 . 19546306 . 10.1096/fj.08-122853 . free . 38515607 .
  19. Richard JE, Farkas I, Anesten F, Anderberg RH, Dickson SL, Gribble FM, Reimann F, Jansson JO, Liposits Z, Skibicka KP . GLP-1 receptor stimulation of the lateral parabrachial nucleus reduces food intake: neuroanatomical, electrophysiological, and behavioral evidence . Endocrinology . 155 . 11 . 4356–4367 . November 2014 . 25116706 . 4256827 . 10.1210/en.2014-1248 .
  20. Anesten F, Mishra D, Dalmau Gasull A, Engström-Ruud L, Bellman J, Palsdottir V, Zhang F, Trapp S, Skibicka KP, Poutanen M, Jansson JO . Glucagon-Like Peptide-1-, but not Growth and Differentiation Factor 15-, Receptor Activation Increases the Number of Interleukin-6-Expressing Cells in the External Lateral Parabrachial Nucleus . Neuroendocrinology . 109 . 4 . 310–321 . 2019 . 30889580 . 10.1159/000499693 . 208014066 .
  21. Mishra D, Richard JE, Maric I, Porteiro B, Häring M, Kooijman S, Musovic S, Eerola K, López-Ferreras L, Peris E, Grycel K, Shevchouk OT, Micallef P, Olofsson CS, Wernstedt Asterholm I, Grill HJ, Nogueiras R, Skibicka KP . Parabrachial Interleukin-6 Reduces Body Weight and Food Intake and Increases Thermogenesis to Regulate Energy Metabolism . Cell Reports . 26 . 11 . 3011–3026.e5 . March 2019 . 30865890 . 6418345 . 10.1016/j.celrep.2019.02.044 .
  22. Febbraio MA, Pedersen BK . Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? . Exercise and Sport Sciences Reviews . 33 . 3 . 114–119 . July 2005 . 16006818 . 10.1097/00003677-200507000-00003 . 26503323 . free .
  23. Petersen AM, Pedersen BK . The anti-inflammatory effect of exercise . Journal of Applied Physiology . 98 . 4 . 1154–1162 . April 2005 . 15772055 . 10.1152/japplphysiol.00164.2004 . 4776835 .
  24. Colbert LH, Davis JM, Essig DA, Ghaffar A, Mayer EP . Tissue expression and plasma concentrations of TNFalpha, IL-1beta, and IL-6 following treadmill exercise in mice . International Journal of Sports Medicine . 22 . 4 . 261–267 . May 2001 . 11414667 . 10.1055/s-2001-13818 . 260192304 .
  25. Jonsdottir IH, Schjerling P, Ostrowski K, Asp S, Richter EA, Pedersen BK . Muscle contractions induce interleukin-6 mRNA production in rat skeletal muscles . The Journal of Physiology . 528 Pt 1 . 157–163 . October 2000 . Pt 1 . 11018114 . 2270126 . 10.1111/j.1469-7793.2000.00157.x .
  26. Fäldt J, Wernstedt I, Fitzgerald SM, Wallenius K, Bergström G, Jansson JO . Reduced exercise endurance in interleukin-6-deficient mice . Endocrinology . 145 . 6 . 2680–2686 . June 2004 . 14988384 . 10.1210/en.2003-1319 .
  27. Wedell-Neergaard AS, Lang Lehrskov L, Christensen RH, Legaard GE, Dorph E, Larsen MK, Launbo N, Fagerlind SR, Seide SK, Nymand S, Ball M, Vinum N, Dahl CN, Henneberg M, Ried-Larsen M, Nybing JD, Christensen R, Rosenmeier JB, Karstoft K, Pedersen BK, Ellingsgaard H, Krogh-Madsen R . Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial . Cell Metabolism . 29 . 4 . 844–855.e3 . April 2019 . 30595477 . 10.1016/j.cmet.2018.12.007 . free .
  28. Chowdhury S, Schulz L, Palmisano B, Singh P, Berger JM, Yadav VK, Mera P, Ellingsgaard H, Hidalgo J, Brüning J, Karsenty G . Muscle-derived interleukin 6 increases exercise capacity by signaling in osteoblasts . The Journal of Clinical Investigation . 130 . 6 . 2888–2902 . June 2020 . 32078586 . 7260002 . 10.1172/JCI133572 .
  29. Pedersen BK, Febbraio MA . Muscle as an endocrine organ: focus on muscle-derived interleukin-6 . Physiological Reviews . 88 . 4 . 1379–1406 . October 2008 . 18923185 . 10.1152/physrev.90100.2007 . 12601630 .
  30. Book: Pedersen BK . Muscle as a secretory organ . Comprehensive Physiology . 3 . 3 . 1337–62 . July 2013 . 23897689 . 10.1002/cphy.c120033 . 9780470650714.
  31. Bruunsgaard H, Galbo H, Halkjaer-Kristensen J, Johansen TL, MacLean DA, Pedersen BK . Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage . The Journal of Physiology . 499 (Pt 3) . 3 . 833–841 . March 1997 . 9130176 . 1159298 . 10.1113/jphysiol.1997.sp021972 .
  32. Brandt C, Pedersen BK . The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases . Journal of Biomedicine & Biotechnology . 2010 . 520258 . 2010 . 20224659 . 2836182 . 10.1155/2010/520258 . free .
  33. Muñoz-Cánoves P, Scheele C, Pedersen BK, Serrano AL . Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? . The FEBS Journal . 280 . 17 . 4131–4148 . September 2013 . 23663276 . 4163639 . 10.1111/febs.12338 .
  34. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L . Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway . The Biochemical Journal . 334 (Pt 2) . Pt 2 . 297–314 . September 1998 . 9716487 . 1219691 . 10.1042/bj3340297 .
  35. Kishimoto T, Akira S, Narazaki M, Taga T . Interleukin-6 family of cytokines and gp130 . Blood . 86 . 4 . 1243–1254 . August 1995 . 7632928 . 10.1182/blood.V86.4.1243.bloodjournal8641243 . free .
  36. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F . Principles of interleukin (IL)-6-type cytokine signalling and its regulation . The Biochemical Journal . 374 . Pt 1 . 1–20 . August 2003 . 12773095 . 1223585 . 10.1042/BJ20030407 .
  37. Schwantner A, Dingley AJ, Ozbek S, Rose-John S, Grötzinger J . Direct determination of the interleukin-6 binding epitope of the interleukin-6 receptor by NMR spectroscopy . The Journal of Biological Chemistry . 279 . 1 . 571–576 . January 2004 . 14557255 . 10.1074/jbc.M311019200 . free .
  38. Schuster B, Kovaleva M, Sun Y, Regenhard P, Matthews V, Grötzinger J, Rose-John S, Kallen KJ . Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF . The Journal of Biological Chemistry . 278 . 11 . 9528–9535 . March 2003 . 12643274 . 10.1074/jbc.M210044200 . free.
  39. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T . Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 . Cell . 58 . 3 . 573–581 . August 1989 . 2788034 . 10.1016/0092-8674(89)90438-8 . 41245022 .
  40. Kallen KJ, zum Büschenfelde KH, Rose-John S . The therapeutic potential of interleukin-6 hyperagonists and antagonists . Expert Opinion on Investigational Drugs . 6 . 3 . 237–266 . March 1997 . 15989626 . 10.1517/13543784.6.3.237 .
  41. Gordon-Alonso M, Bruger AM, van der Bruggen P . Extracellular galectins as controllers of cytokines in hematological cancer . Blood . 132 . 5 . 484–491 . August 2018 . 29875102 . 6073326 . 10.1182/blood-2018-04-846014 .
  42. Kong BS, Kim Y, Kim GY, Hyun JW, Kim SH, Jeong A, Kim HJ . Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder . Journal of Neuroinflammation . 14 . 1 . 191 . September 2017 . 28946890 . 5613387 . 10.1186/s12974-017-0961-z . free .
  43. Kristiansen OP, Mandrup-Poulsen T . Interleukin-6 and diabetes: the good, the bad, or the indifferent? . Diabetes . 54 . S114–S124 . December 2005 . Suppl 2 . 16306329 . 10.2337/diabetes.54.suppl_2.S114 . free .
  44. Dubiński A, Zdrojewicz Z . [The role of interleukin-6 in development and progression of atherosclerosis] . pl . Polski Merkuriusz Lekarski . 22 . 130 . 291–294 . April 2007 . 17684929 .
  45. Yu B, de Vos D, Guo X, Peng S, Xie W, Peppelenbosch MP, Fu Y, Fuhler GM . IL-6 facilitates cross-talk between epithelial cells and tumor- associated macrophages in Helicobacter pylori-linked gastric carcinogenesis. . Neoplasia . 50 . 100981 . April 2024 . 38422751 . 10912637 . 10.1016/j.neo.2024.100981 . free.
  46. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL . A meta-analysis of cytokines in major depression . Biological Psychiatry . 67 . 5 . 446–457 . March 2010 . 20015486 . 10.1016/j.biopsych.2009.09.033 . 230209 .
  47. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N . A meta-analysis of cytokines in Alzheimer's disease . Biological Psychiatry . 68 . 10 . 930–941 . November 2010 . 20692646 . 10.1016/j.biopsych.2010.06.012 . 6544784 .
  48. Tackey E, Lipsky PE, Illei GG . Rationale for interleukin-6 blockade in systemic lupus erythematosus . Lupus . 13 . 5 . 339–343 . 2004 . 15230289 . 2014821 . 10.1191/0961203304lu1023oa .
  49. Gadó K, Domján G, Hegyesi H, Falus A . Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma . Cell Biology International . 24 . 4 . 195–209 . 2000 . 10816321 . 10.1006/cbir.2000.0497 . 44820455 .
  50. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET . Interleukin-6 and prostate cancer progression . Cytokine & Growth Factor Reviews . 12 . 1 . 33–40 . March 2001 . 11312117 . 10.1016/S1359-6101(00)00021-6 .
  51. Hirohata S, Kikuchi H . Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet's disease . Internal Medicine . 51 . 24 . 3359–3365 . Dec 2012 . 23257520 . 10.2169/internalmedicine.51.8583 . free .
  52. Nishimoto N . Interleukin-6 in rheumatoid arthritis . Current Opinion in Rheumatology . 18 . 3 . 277–281 . May 2006 . 16582692 . 10.1097/01.bor.0000218949.19860.d1 . 20188179 .
  53. Zhu H, Wang Z, Yu J, Yang X, He F, Liu Z, Che F, Chen X, Ren H, Hong M, Wang J . Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage . Progress in Neurobiology . 178 . 101610 . July 2019 . 30923023 . 10.1016/j.pneurobio.2019.03.003 . 85495400 .
  54. Barton BE . Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes . Expert Opinion on Therapeutic Targets . 9 . 4 . 737–752 . August 2005 . 16083340 . 10.1517/14728222.9.4.737 . 45421426 .
  55. Smolen JS, Maini RN . Interleukin-6: a new therapeutic target . Arthritis Research & Therapy . 8 . Suppl 2 . S5 . 2006 . 16899109 . 3226077 . 10.1186/ar1969 . free .
  56. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J . IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial . Annals of the Rheumatic Diseases . 67 . 11 . 1516–1523 . November 2008 . 18625622 . 3811149 . 10.1136/ard.2008.092932 .
  57. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T . Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease . Blood . 106 . 8 . 2627–2632 . October 2005 . 15998837 . 10.1182/blood-2004-12-4602 . free .
  58. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T . Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial . Lancet . 371 . 9617 . 998–1006 . March 2008 . 18358927 . 10.1016/S0140-6736(08)60454-7 . 21554759 .
  59. http://www.nature.com/nm/journal/v19/n10/full/nm1013-1193.html First IL-6–blocking drug nears approval for rare blood disorder
  60. April 2019 . Genetic Inactivation of ZCCHC6 Suppresses Interleukin-6 Expression and Reduces the Severity of Experimental Osteoarthritis in Mice . Arthritis & Rheumatology . 71 . 4 . 583–593 . 10.1002/art.40751 . 2326-5205 . 6438766 . 30302948. Ansari MY, Khan NM, Ahmad N, Green J, Novak K, Haqqi TM.
  61. 2018 . Butein Activates Autophagy Through AMPK/TSC2/ULK1/mTOR Pathway to Inhibit IL-6 Expression in IL-1β Stimulated Human Chondrocytes . Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology . 49 . 3 . 932–946 . 10.1159/000493225 . 1421-9778 . 30184535. 52166938. Ansari MY, Ahmad N, Haqqi TM . free .
  62. Gao B, Ahmad MF, Nagy LE, Tsukamoto H . Inflammatory pathways in alcoholic steatohepatitis . Journal of Hepatology . 70 . 2 . 249–259 . February 2019 . 30658726 . 6361545 . 10.1016/j.jhep.2018.10.023 .
  63. Remmler J, Schneider C, Treuner-Kaueroff T, Bartels M, Seehofer D, Scholz M, Berg T, Kaiser T . Increased Level of Interleukin 6 Associates With Increased 90-Day and 1-Year Mortality in Patients With End-Stage Liver Disease . Clinical Gastroenterology and Hepatology . 16 . 5 . 730–737 . May 2018 . 28919544 . 10.1016/j.cgh.2017.09.017 . 4408167 .
  64. Zhou C, Zhang N, He TT, Wang Y, Wang LF, Sun YQ, Jing J, Zhang JJ, Fu SN, Wang X, Liang XX, Li X, Gong M, Li J . High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure . World Journal of Gastroenterology . 26 . 30 . 4479–4488 . August 2020 . 32874059 . 7438191 . 10.3748/wjg.v26.i30.4479 . free .
  65. Sheron N, Bird G, Goka J, Alexander G, Williams R . Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis . Clinical and Experimental Immunology . 84 . 3 . 449–453 . June 1991 . 2044224 . 1535433 .
  66. Arroyo V, Angeli P, Moreau R, Jalan R, Clària J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M . The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis . Journal of Hepatology . 74 . 3 . 670–685 . March 2021 . 33301825 . 10.1016/j.jhep.2020.11.048 . free . 2445/175350 .
  67. Tornai D, Mitchell M, McClain CJ, Dasarathy S, McCullough A, Radaeva S, Kroll-Desrosiers A, Lee J, Barton B, Szabo G . A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: A multicenter plasma biomarker analysis . Hepatology Communications . 7 . 12 . December 2023 . 37994498 . 10666984 . 10.1097/HC9.0000000000000296 .
  68. Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA . TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis . Cytokine . 89 . 127–135 . January 2017 . 26854213 . 10.1016/j.cyto.2016.01.021 .
  69. Anestakis D, Petanidis S, Kalyvas S, Nday CM, Tsave O, Kioseoglou E, Salifoglou A . Mechanisms and applications of interleukins in cancer immunotherapy . International Journal of Molecular Sciences . 16 . 1 . 1691–1710 . January 2015 . 25590298 . 4307328 . 10.3390/ijms16011691 . free .
  70. Mei Y, Ren K, Liu Y, Ma A, Xia Z, Han X, Li E, Tariq H, Bao H, Xie X, Zou C, Zhang D, Li Z, Dong L, Verma A, Lu X, Abaza Y, Altman JK, Sukhanova M, Yang J, Ji P . Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia . The Journal of Clinical Investigation . 132 . 17 . e152673 . September 2022 . 35900794 . 9435651 . 10.1172/JCI152673 .
  71. Li J, Mo HY, Xiong G, Zhang L, He J, Huang ZF, Liu ZW, Chen QY, Du ZM, Zheng LM, Qian CN, Zeng YX . Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients . The Journal of Biological Chemistry . 287 . 42 . 35484–35495 . October 2012 . 22893706 . 3471767 . 10.1074/jbc.M112.367532 . free .
  72. Xie G, Yao Q, Liu Y, Du S, Liu A, Guo Z, Sun A, Ruan J, Chen L, Ye C, Yuan Y . IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures . International Journal of Oncology . 40 . 4 . 1171–1179 . April 2012 . 22134360 . 3584811 . 10.3892/ijo.2011.1275 .
  73. Miao JW, Liu LJ, Huang J . Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma . International Journal of Oncology . 45 . 1 . 165–176 . July 2014 . 24806843 . 10.3892/ijo.2014.2422 . free .
  74. Gasche JA, Hoffmann J, Boland CR, Goel A . Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells . International Journal of Cancer . 129 . 5 . 1053–1063 . September 2011 . 21710491 . 3110561 . 10.1002/ijc.25764 .
  75. Web site: Cancer Patients Typically Have Increased Interleukin-6 Levels . 2006-06-26 . American Society of Clinical Oncology 2006 Annual Meeting, Abstracts 8632 and 8633 . Medscape.com.
  76. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M, Emanuelli G . Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival . Cancer Immunology, Immunotherapy . 55 . 6 . 684–698 . June 2006 . 16094523 . 10.1007/s00262-005-0047-0 . 11031060 . 11019678 .
  77. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH . Maternal immune activation alters fetal brain development through interleukin-6 . The Journal of Neuroscience . 27 . 40 . 10695–10702 . October 2007 . 17913903 . 2387067 . 10.1523/JNEUROSCI.2178-07.2007 .
  78. Kundakovic M, Chen Y, Guidotti A, Grayson DR . The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes . Molecular Pharmacology . 75 . 2 . 342–354 . February 2009 . 19029285 . 2684898 . 10.1124/mol.108.051763 .
  79. Hodge DR, Cho E, Copeland TD, Guszczynski T, Yang E, Seth AK, Farrar WL . IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase . Cancer Genomics & Proteomics . 4 . 6 . 387–398 . 2007 . 18204201 .
  80. Foran E, Garrity-Park MM, Mureau C, Newell J, Smyrk TC, Limburg PJ, Egan LJ . Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6 . Molecular Cancer Research . 8 . 4 . 471–481 . April 2010 . 20354000 . 10.1158/1541-7786.MCR-09-0496 . free .
  81. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E, DiGiorgi Gerevini V . Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study . Archives of General Psychiatry . 57 . 11 . 1061–1069 . November 2000 . 11074872 . 10.1001/archpsyc.57.11.1061 .
  82. Gandal MJ, Sisti J, Klook K, Ortinski PI, Leitman V, Liang Y, Thieu T, Anderson R, Pierce RC, Jonak G, Gur RE, Carlson G, Siegel SJ . GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction . Translational Psychiatry . 2 . 7 . e142 . July 2012 . 22806213 . 3410621 . 10.1038/tp.2012.69 .
  83. Uhlhaas PJ, Singer W . Abnormal neural oscillations and synchrony in schizophrenia . Nature Reviews. Neuroscience . 11 . 2 . 100–113 . February 2010 . 20087360 . 10.1038/nrn2774 . 205505539 .
  84. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J . Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor . PLOS Biology . 6 . 12 . 2853–2868 . December 2008 . 19053174 . 2592359 . 10.1371/journal.pbio.0060301 . free .
  85. Childs BG, Gluscevic M, Baker DJ, Laberge RM, Marquess D, Dananberg J, van Deursen JM . Senescent cells: an emerging target for diseases of ageing . Nature Reviews. Drug Discovery . 16 . 10 . 718–735 . October 2017 . 28729727 . 5942225 . 10.1038/nrd.2017.116 .
  86. Kim YH, Park TJ . Cellular senescence in cancer . BMB Reports . 52 . 1 . 42–46 . January 2019 . 30526772 . 6386235 . 10.5483/BMBRep.2019.52.1.295 .
  87. Partridge L, Fuentealba M, Kennedy BK . The quest to slow ageing through drug discovery . Nature Reviews. Drug Discovery . 19 . 8 . 513–532 . August 2020 . 32467649 . 10.1038/s41573-020-0067-7 . 218912510 .
  88. Sharma RP, Tun N, Grayson DR . Depolarization induces downregulation of DNMT1 and DNMT3a in primary cortical cultures . Epigenetics . 3 . 2 . 74–80 . 2008 . 18536530 . 10.4161/epi.3.2.6103 . free .
  89. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF, Yang YM . The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression . Neurobiology of Aging . 27 . 12 . 1834–1837 . December 2006 . 16343697 . 10.1016/j.neurobiolaging.2005.10.013 . 23626890 .
  90. Ethell IM, Pasquale EB . Molecular mechanisms of dendritic spine development and remodeling . Progress in Neurobiology . 75 . 3 . 161–205 . February 2005 . 15882774 . 10.1016/j.pneurobio.2005.02.003 . 24889257 .
  91. Gary H. Glover . Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF . Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus . Biological Psychiatry . 62 . 5 . 429–437 . September 2007 . 17210143 . 2001244 . 10.1016/j.biopsych.2006.09.020 .
  92. Somerville LH, Heatherton TF, Kelley WM . Anterior cingulate cortex responds differentially to expectancy violation and social rejection . Nature Neuroscience . 9 . 8 . 1007–1008 . August 2006 . 16819523 . 10.1038/nn1728 . 35224855 .
  93. Azzolina A, Bongiovanni A, Lampiasi N . Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells . Biochimica et Biophysica Acta (BBA) - Molecular Cell Research . 1643 . 1–3 . 75–83 . December 2003 . 14654230 . 10.1016/j.bbamcr.2003.09.003 .
  94. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M . Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder . Brain, Behavior, and Immunity . 49 . 206–215 . October 2015 . 26065825 . 4566946 . 10.1016/j.bbi.2015.06.001 .
  95. Ratti E, Bettica P, Alexander R, Archer G, Carpenter D, Evoniuk G, Gomeni R, Lawson E, Lopez M, Millns H, Rabiner EA, Trist D, Trower M, Zamuner S, Krishnan R, Fava M . Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies . Journal of Psychopharmacology . 27 . 5 . 424–434 . May 2013 . 23539641 . 10.1177/0269881113480990 . 6523822 .
  96. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM . Distinct mechanism for antidepressant activity by blockade of central substance P receptors . Science . 281 . 5383 . 1640–1645 . September 1998 . 9733503 . 10.1126/science.281.5383.1640 . 1998Sci...281.1640K .
  97. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB . Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings . The American Journal of Psychiatry . 158 . 8 . 1252–1257 . August 2001 . 11481159 . 10.1176/appi.ajp.158.8.1252 .
  98. Zhu GF, Chancellor-Freeland C, Berman AS, Kage R, Leeman SE, Beller DI, Black PH . Endogenous substance P mediates cold water stress-induced increase in interleukin-6 secretion from peritoneal macrophages . The Journal of Neuroscience . 16 . 11 . 3745–3752 . June 1996 . 8642417 . 6578844 . 10.1523/JNEUROSCI.16-11-03745.1996 .
  99. Web site: Sirukumab - Janssen Biotech . AdisInsight . Springer Nature Switzerland AG .
  100. Peters MC, McGrath KW, Hawkins GA, Hastie AT, Levy BD, Israel E, Phillips BR, Mauger DT, Comhair SA, Erzurum SC, Johansson MW, Jarjour NN, Coverstone AM, Castro M, Holguin F, Wenzel SE, Woodruff PG, Bleecker ER, Fahy JV . Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts . The Lancet. Respiratory Medicine . 4 . 7 . 574–584 . July 2016 . 27283230 . 5007068 . 10.1016/S2213-2600(16)30048-0 .
  101. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S . HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice . Blood . 119 . 22 . 5173–5181 . May 2012 . 22490805 . 3370672 . 10.1182/blood-2011-09-377705 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Interleukin 6".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.